Tags

Type your tag names separated by a space and hit enter

[Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease].
Rev Neurol. 1999 May 1-15; 28(9):889-98.RN

Abstract

OBJECTIVE

The progression of Parkinson's disease (PD) and levodopa therapy leads to development of motor and psychic complications that cause serious limitations to the management of the advanced disease.

DEVELOPMENT

This article reviews the current literature regarding epidemiological, clinical, pathophysiological and therapeutics of levodopa-induced dyskinesias (LID).

CONCLUSIONS

1) The most important risk factors for LID are the cumulated doses of levodopa, young age at onset and severity of PD. 2) Pathophysiological data include the nigrostriatal system denervation, the prolonged exposure to levodopa and the integrity of striatal eferences; in addition there are some alterations of dopamine receptors and other neurotransmitter systems. 3) Some pharmacological measures, different for each type of LID, and surgery (pallidotomy, pallidal stimulation, subthalamic stimulation) can be useful for the therapy of LID.

Authors+Show Affiliations

Servicio de Neurología, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, España. fjimenezj@meditex.esNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

spa

PubMed ID

10390756

Citation

Jiménez-Jiménez, F J., et al. "[Pharmacological Mechanisms of the Treatment of Dyskinesias in Parkinson Disease]." Revista De Neurologia, vol. 28, no. 9, 1999, pp. 889-98.
Jiménez-Jiménez FJ, Molina JA, Ortí-Pareja M. [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Rev Neurol. 1999;28(9):889-98.
Jiménez-Jiménez, F. J., Molina, J. A., & Ortí-Pareja, M. (1999). [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. Revista De Neurologia, 28(9), 889-98.
Jiménez-Jiménez FJ, Molina JA, Ortí-Pareja M. [Pharmacological Mechanisms of the Treatment of Dyskinesias in Parkinson Disease]. Rev Neurol. 1999 May 1-15;28(9):889-98. PubMed PMID: 10390756.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Pharmacological mechanisms of the treatment of dyskinesias in Parkinson disease]. AU - Jiménez-Jiménez,F J, AU - Molina,J A, AU - Ortí-Pareja,M, PY - 1999/7/3/pubmed PY - 1999/7/3/medline PY - 1999/7/3/entrez SP - 889 EP - 98 JF - Revista de neurologia JO - Rev Neurol VL - 28 IS - 9 N2 - OBJECTIVE: The progression of Parkinson's disease (PD) and levodopa therapy leads to development of motor and psychic complications that cause serious limitations to the management of the advanced disease. DEVELOPMENT: This article reviews the current literature regarding epidemiological, clinical, pathophysiological and therapeutics of levodopa-induced dyskinesias (LID). CONCLUSIONS: 1) The most important risk factors for LID are the cumulated doses of levodopa, young age at onset and severity of PD. 2) Pathophysiological data include the nigrostriatal system denervation, the prolonged exposure to levodopa and the integrity of striatal eferences; in addition there are some alterations of dopamine receptors and other neurotransmitter systems. 3) Some pharmacological measures, different for each type of LID, and surgery (pallidotomy, pallidal stimulation, subthalamic stimulation) can be useful for the therapy of LID. SN - 0210-0010 UR - https://www.unboundmedicine.com/medline/citation/10390756/[Pharmacological_mechanisms_of_the_treatment_of_dyskinesias_in_Parkinson_disease]_ L2 - http://www.diseaseinfosearch.org/result/5603 DB - PRIME DP - Unbound Medicine ER -